By GlobeNewswire, March 21, 2013, 12:44:00 PM EDT
STERLING, Va., March 21, 2013 (GLOBE NEWSWIRE) -- InferX Corporation (OTCPK:NFRX) announced today appointment of two new members to the InferX Management Advisory Board.
Lawrence Hoffman is a Senior Partner at Raffa P.C., a regional accounting firm based in Washington, D.C., and brings strong qualifications in the financial sector, with particular strengths in the area of forensic accounting and fraud/risk assessment. Building on InferX's prior work with a "Big Four" accounting firm identifying suspect transactions, we are working with Mr. Hoffman to explore creating an analysis practice area to support new CA/CM capabilities ('Continuous Auditing/Continuous Monitoring') which we believe is a high priority among major corporations.
Oliver Alabaster, M.D. is an Oncologist and was a Professor at the GWU Medical Center in Washington, D.C. where he was Director of Cancer Research for twenty years and also the Director of the Institute for Disease Prevention. Dr. Alabaster helped to found the Prevent Cancer Foundation in 1986 and was formerly Vice-Chairman of the Board. He has agreed to assist InferX in developing a predictive analytics solution to identify patients with a high risk of cancer. The proposed solution would be similar to the analytics framework used by InferX to successfully develop the Acute Kidney Injury ("AKI") proof of concept in cooperation with leading researchers in Nephrology at the GWU Medical Center.
The new appointments further complement the Company's existing Management Advisory Board and additional appointments are expected.
InferX pioneered and commercialized a powerful, proprietary suite of predictive data analysis technologies and tools. The Company has two patents issued for its real time, distributed predictive analytics and business intelligence system.
"Developing innovative new solutions to improve performance, reduce costs, increase revenues and even help save lives- that is how next generation analytics is driving today's today's IT revolution, said Paul B. Silverman, InferX CEO and President. "We are changing traditional rules of market, strategy,and operations analysis, driving economic growth, and creating exciting new opportunities. I am pleased Lawrence Hoffman and Dr. Alabaster have joined the InferX team and welcome their support helping InferX meet its ambitious growth objectives in the financial services and healthcare sectors," said Silverman.
About InferX Corporation
InferX is the market leader in next generation distributed Predictive Analytics and Business Intelligence Products and Solutions. InferX has pioneered and commercialized a powerful, patented suite of advanced data analytical solutions that improve corporate performance across the enterprise in the healthcare, financial services, and government markets. InferX is uniquely capable of delivering secure, real-time, and privacy preserving intelligence and decision support — all without the need to move data.InferX is headquartered in Sterling, VA.
For more information go to the InferX website www.inferx.com.
Certain statements above, in press releases and NFRX officials oral statements are "Forward-Looking Statements" (FLS) according to the Private Securities Litigation Reform Act of 1995 (the "Act"). FLS include statements predictive in nature, depending upon or referring to future events / conditions, including words like "believes," "anticipates," "intends," "plans," "expects," and similar expressions. Statements concerning future financial performance (revenues, earnings, and growth rates), ongoing business strategies / prospects, and future actions, which may be provided by management, are also FLS as defined by the Act. The actual and any future results, performance or achievements of the Company, expressed or implied, may be materially different and vary significantly for different reporting periods due to FLS that involve known and unknown risks and other factors. See InferX's 10-K for 12/31/11 for a discussion of those risks. Management believes that the assumptions made and expectations reflected in the FLS are reasonable. There is no assurance that the underlying assumptions will prove to be correct and the actual future results may be different from expectations expressed above. These statements are not guarantees of future performance. NFRX has no specific intention to update these statements.
©2013 InferX Corporation. All rights reserved. All trademarks and company names mentioned are the property of their respective owners.
CONTACT: InferX Corporation
Fax 703-444 2119
Stuart T. Smith
Source: InferX Corporation